|1.||Owens, Ian J: 1 article (03/2011)|
|2.||McTighe, Stephanie M: 1 article (03/2011)|
|3.||Bansal, Aruna T: 1 article (03/2011)|
|4.||Bussey, Timothy J: 1 article (03/2011)|
|5.||McCarthy, Alun D: 1 article (03/2011)|
|6.||Saksida, Lisa M: 1 article (03/2011)|
|7.||Wang, Feng: 1 article (12/2005)|
|8.||Matsuoka, Nobuya: 1 article (12/2005)|
|9.||Inoue, Tatsuo: 1 article (12/2005)|
|10.||Mutoh, Seitaro: 1 article (12/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
12/19/2005 - "These results suggest that FK962 ameliorates cognitive impairment in rats via activation of the somatostatinergic nervous system in the hippocampus, indicating that FK962 could be a potent cognitive enhancer and therefore might be of therapeutic value for cognitive disorders such as Alzheimer's disease."
03/01/2011 - "FK962 is a member of a novel class of compounds that promote somatostatin production in the brain, and is being developed as a treatment for patients with Alzheimer's disease. "
03/01/2011 - "FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease."
|2.||Memory Disorders (Memory Loss)
12/19/2005 - "FK962 (0.01- 1) mg/kg, i.p.) significantly improved spatial memory deficits induced by nucleus basalis magnocellularis-lesion in water maze task. "
12/19/2005 - "Furthermore, administration of FK962 (0.032-3.2 mg/kg, i.p.) significantly ameliorated memory deficits in passive avoidance task in animal models: scopolamine-treated rats, nucleus basalis magnocellularis-lesioned rats and aged rats. "
|1.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|3.||N-(4-acetyl-1-piperazinyl) -4-fluorobenzamide monohydrate